Drugs / CD40-ligand
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00020540 | Mar 2001 → ? | cutaneous melanoma, kidney cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00053391 | Oct 2002 → Jun 2005 | cutaneous melanoma | University Hospital Erlangen | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00006113 Background | Jun 1999 → May 2003 | cutaneous melanoma | University of Southern California | Terminated | No outcome recorded |
| Phase 2 | NCT00001564 Background | Dec 1996 → Oct 2007 | Ewing sarcoma, rhabdomyosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-09-12 | Targovax Oy | Results Targovax announces publication of new oncolytic virus data in the Journal of Medical Virology and Cancer Gene Therapy circio.com ↗
The study shows that ONCOS-401 produces functional CD40L, and also describes a rapid and simple assay to quantify the efficacy of CD40L production in vitro . |
All press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD40 ligand | “recombinant CD40-ligand” NCT00053391 ↗ |
| Action | Activate | “Tumor necrosis factor receptor superfamily member 5 agonist” CHEMBL4297718 ↗ |
| Modality | Protein / enzyme biologic | “recombinant CD40-ligand” NCT00020540 ↗ |
| Route | Subcutaneous | “CD40-ligand SC daily on days 12-16” NCT00020540 ↗ |
| Target | CD40 | “Tumor necrosis factor receptor superfamily member 5 agonist” CHEMBL4297718 ↗ |